|
![]() |
|
|
Hyoscyamine: profile and news
From the analyst's couch: The IBS market Feb 15, 2006 Inkine Pharmaceutical Announces Approval of Merger with Salix ... Sep 30, 2005 InKine Reports Seven INKP-102 Study Data Abstracts Accepted for ... Aug 4, 2005 Italy: Lettuce uncovered as sexual stimulant Jun 29, 2005 InKine Announces Final Court Approval in Securities Class Action ... Jun 16, 2005 InKine Announces Final Court Approval in Securities Class Action ... Jun 16, 2005 Inkine's Visicol Tablets Associated with Significantly Less After ... May 19, 2005 InKine CEO To Present at the Rodman & Renshaw Techvest 2nd Annual ... 29 Apr 2005 Inappropriate medication prescribed to elderly Mar 8, 2005 Almost One In Three Seniors Given Inappropriate Meds Feb 26, 2005 InKine to Present at BIO CEO & Investor Conference Feb 17, 2005 Almost One In Three Seniors Given Inappropriate Meds Feb 25, 2005 With Positive INKP-102 Results, InKine Prepares For NDA Filing Feb 22, 2005 Other information Indication For treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Hyoscyamine may also be used to treat certain heart conditions, to control the symptoms of Parkinson's disease and rhinitis Pharmacology L-Hyoscyamine, the active optical isomer of atropine (dl-hyoscyamine), is a tertiary amine anticholinergic gastrointestinal agent. Hyoscyamine is used to manage peptic ulcer disease, biliary tract disorders, cystitis, severe allergic rhinitis, hypermotility disorders of the lower urinary tract, infant colic, and to control salivation and excessive secretions before an operation. Mechanism Of Action Hyoscyamine competes favorably with acetylcholine for binding at muscarinic receptors in the salivary, bronchial, and sweat glands as well as in the eye, heart, and gastrointestinal tract. The actions of hyoscyamine result in a reduction in salivary, bronchial, gastric and sweat gland secretions, mydriasis, cycloplegia, change in heart rate, contraction of the bladder detrusor muscle and of the gastrointestinal smooth muscle, and decreased gastrointestinal motility. Drug Category Mydriatics; Bronchodilator Agents; Antiarrhythmic Agents; Adjuvants; Antimuscarinics; Antispasmodics; ATC:A03BA03 Brand Names/Synonyms ATROPINE; Anaspaz; Cystospaz; Daturine; Duboisine; Duretter; Egacene; Egazil; Gastrosed; Hyocyamine; Hyoscyamine; Hyoscyamine, L-; L-Atropine; L-Hyopscyamine; L-Hyoscamine; L-Hyoscyamine; L-Hyoscyamine Free Base; L-Tropine Tropate; Levbid; Levsin; Levsinex; OIN; Peptard; Scopolia Extract Dosage Forms Oral tablets, oral drops, elixir, injection Absorption absorbed totally and completely by sublingual administration as well as oral administration Interactions Interactions for Hyoscyamine: Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines. Antacids may interfere with the absorption of LEVSIN. Administer LEVSIN before meals; antacids after meals. Chemical IUPAC Name (8-methyl-8-azabicyclo[3.2.1]oct-3-yl)3-hydroxy-2-phenyl-propanoate Chemical Formula C17H23NO3 Half Life 2-3 1/2 hours Drug Type Approved Drug # Accession No APRD00607 CAS Registry Number 101-31-5 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |